Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review

RATIONALE: Anaplastic lymphoma kinase (ALK) inhibitors have been approved for patients with ALK-rearrangement lung cancer. The effect is superior to the standard first-line therapy of pemetrexed plus platinum-based chemotherapy. However, ALK inhibitors are associated with rare and sometimes fatal ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yonghui, Chen, Huiguo, Guan, Jiexia, Zhang, Kai, Wu, Weibin, Li, Xiaojun, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257840/
https://www.ncbi.nlm.nih.gov/pubmed/34190169
http://dx.doi.org/10.1097/MD.0000000000026449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257840/
https://www.ncbi.nlm.nih.gov/pubmed/34190169
http://dx.doi.org/10.1097/MD.0000000000026449

Ejemplares similares